关注
Sebastian Bauer
Sebastian Bauer
Professor Translational Oncology
在 uni-due.de 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...
The Lancet 381 (9863), 295-302, 2013
14972013
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ...
Jama 307 (12), 1265-1272, 2012
11682012
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ...
Annals of Oncology 29, iv51-iv67, 2018
8882018
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ...
The Lancet 387 (10028), 1629-1637, 2016
7832016
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ...
Annals of Oncology 29, iv68-iv78, 2018
5872018
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ...
Annals of Oncology 29, iv79-iv95, 2018
5352018
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ...
Annals of Oncology 32 (11), 1348-1365, 2021
5192021
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors
G Antoch, J Kanja, S Bauer, H Kuehl, K Renzing-Koehler, J Schuette, ...
Journal of Nuclear Medicine 45 (3), 357-365, 2004
4352004
An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European organization for …
B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, ...
Annals of Oncology 28 (10), 2399-2408, 2017
3952017
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
JY Blay, C Serrano, MC Heinrich, J Zalcberg, S Bauer, H Gelderblom, ...
The Lancet Oncology 21 (7), 923-934, 2020
3382020
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ...
The Lancet 394 (10197), 478-487, 2019
3372019
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
S Bauer, LK Yu, GD Demetri, JA Fletcher
Cancer research 66 (18), 9153-9161, 2006
3282006
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S Bauer, A Duensing, GD Demetri, JA Fletcher
Oncogene 26 (54), 7560-7568, 2007
3202007
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience
P Rutkowski, A Gronchi, P Hohenberger, S Bonvalot, P Schöffski, S Bauer, ...
Annals of surgical oncology 20, 2937-2943, 2013
2852013
Narrow Window in Nanoscale Dependent Activation of Endothelial Cell Growth and Differentiation on TiO2 Nanotube Surfaces
J Park, S Bauer, P Schmuki, K Von Der Mark
Nano letters 9 (9), 3157-3164, 2009
2822009
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ...
Annals of oncology 33 (1), 20-33, 2022
2772022
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
MC Heinrich, RL Jones, M von Mehren, P Schöffski, C Serrano, YK Kang, ...
The Lancet Oncology 21 (7), 935-946, 2020
2652020
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
P Schöffski, IL Ray-Coquard, A Cioffi, NB Bui, S Bauer, JT Hartmann, ...
The lancet oncology 12 (11), 1045-1052, 2011
2442011
Integrative genomic and transcriptomic analysis of leiomyosarcoma
P Chudasama, SS Mughal, MA Sanders, D Hübschmann, I Chung, ...
Nature communications 9 (1), 144, 2018
2402018
Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial
H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ...
Journal of Clinical Oncology 34 (3), 244-250, 2016
2362016
系统目前无法执行此操作,请稍后再试。
文章 1–20